Among the most promising tools of cancer therapy, engineered immune cells known as chimeric antigen-receptor (CAR) T cells ...

Creative Biolabs is accelerating CAR‑T innovation, driving breakthroughs in solid tumor targeting. SHIRLEY, NY, UNITED ...

In 2024, Professor Sebastian Kobold's research group at LMU University Hospital had already shown that the metabolite ...

The CAR T-cell therapy market is ripe for growth with over 250 companies and 500 drugs in development globally. Key opportunities lie in targeting hematologic malignancies and overcoming challenges in ...

By Hugo Francisco de Souza A novel CAR-T cell approach targets amyloid plaques in preclinical Alzheimer models, raising the ...

Colleen Mabasa, a patient with multiple myeloma, sat down with CURE for an interview to discuss how she pursued chimeric antigen receptor (CAR)-T cell therapy, navigated insurance and logistical ...

Symptoms and organ damage abated in young children and teenagers whose conditions had resisted other treatments.

A method called "in vivo CAR-T (in vivo CAR-T·intra-body CAR-T)" that directly alters immune cells within the body with a single injection is recently changing the landscape of the cancer treatment ...

CAR T-cell therapy shows promise for SCLC, but significant barriers, such as tumor heterogeneity and immunosuppression, must be addressed. Identifying tumor-selective antigens like CDH17, GD2, and ...

While earlier-line BCMA CAR T-cell therapy in multiple myeloma offers superior efficacy and longer treatment-free survival, careful monitoring and further research are needed to manage rare but ...

According to MarketsandMarkets™, the CAR T-Cell Therapy Market is estimated to reach USD 13.78 billion by 2031 from USD 7.24 billion in 2026, at a CAGR of 13.7%.